EMEA-002762-PIP02-20-M02 - paediatric investigation plan
denecimig
PIPHuman
Key facts
- Active Substance
- denecimig
- Therapeutic area
- Blood and lymphatic system disorders
- Decision number
- P/0477/2023
- PIP number
- EMEA-002762-PIP02-20-M02
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of Haemophilia A
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Novo Nordisk A/S
E-mail: paediatrics@novonordisk.com
Tel.: +45 44448888- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date